ライフサイエンスコーパス: stimulating factor

1 chemotactic protein-1 and macrophage colony-stimulating factor).

2 phenotype with granulocyte-macrophage colony-stimulating factor.

3 t of IL-10 and granulocyte-macrophage colony-stimulating factor.

4 ctor-alpha and granulocyte macrophage colony-stimulating factor.

5 ponsiveness to granulocyte-macrophage colony-stimulating factor.

6 except CTLA-4/granulocyte macrophage colony-stimulating factor.

7 a, IL-17A, and granulocyte-macrophage colony-stimulating factor.

8 factor kappa-B ligand, and macrophage colony-stimulating factor.

9 fection, starvation and by macrophage colony-stimulating factor.

10 odified recombinant human granulocyte-colony stimulating factor.

11 and 2, and the granulocyte macrophage colony-stimulating factor.

12 t or genetic deficiency of macrophage colony-stimulating factor.

13 tor alpha, and granulocyte-macrophage colony-stimulating factor.

14 sibly also for granulocyte-macrophage colony-stimulating factor.

15 ravenous antibiotics; and addition of colony-stimulating factors.

16 is factor inhibitors, and granulocyte colony-stimulating factors.

17 nd augments systemic levels of hematopoiesis-stimulating factors.

18 h gamma interferon (IFN-gamma) DNA or colony-stimulating factor 1 (CSF-1) DNA prior to ocular infecti

19 Colony-stimulating factor 1 (CSF-1), the cytokine acting as the

20 hat alloantibody can, in concert with colony-stimulating factor 1 (CSF-1)-dependent donor macrophages

21 resses OC differentiation by limiting colony-stimulating factor 1 (CSF-1)-dependent proliferation and

22 alizing antibodies against macrophage colony-stimulating factor 1 (CSF1 or MCSF) or F4/80.

23 Expression of the colony-stimulating factor 1 (CSF1) gene is elevated in most ten

24 injury induced de novo expression of colony-stimulating factor 1 (CSF1) in injured sensory neurons.

25 Viral-mediated knockdown of neuronal colony stimulating factor 1 (CSF1) was used to modulate microgl

26 nflammatory response genes, including colony-stimulating factor 1 (CSF1), a central regulator of macr

27 characterised by an overexpression of colony-stimulating factor 1 (CSF1), and is usually caused by a

28 the tumor cells to express macrophage colony-stimulating factor 1 (M-CSF1 or CSF1) and other cytokine

29 In response to liver injury, colony-stimulating factor 1 drives early monocyte-mediated myof

30 Conversely, incubation of colony-stimulating factor 1 macrophages with E2 increased conce

31 -to-tumour heterogeneity, response to colony-stimulating factor 1 receptor (CSF-1R) blockade and nano

32 onal events and signals downstream of colony-stimulating factor 1 receptor (CSF-1R) that contributes

33 acrophages induces phosphorylation of colony-stimulating factor 1 receptor (CSF-1R), which confers re

34 Depletion of immunosuppressive, colony stimulating factor 1 receptor (CSF-1R)-dependent arginas

35 Mutations in the colony stimulating factor 1 receptor (CSF1R) have recently been

36 vered that microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for surv

37 in the healthy adult mouse depend on colony-stimulating factor 1 receptor (CSF1R) signalling for sur

38 is regulated by the activation of the colony-stimulating factor 1 receptor (CSF1R), thus providing a

39 ophages through its inhibition of the colony stimulating factor 1 receptor (CSF1R).

40 In contrast, colony-stimulating factor 1 receptor blockade diminished C-C ch

41 ealed a novel mutation p.R782G in the Colony-Stimulating Factor 1 Receptor gene (CSF1R).

42 at treatment with the pharmacological colony stimulating factor 1 receptor inhibitor PLX5622 specific

43 mice depleted of microglia by using a colony-stimulating factor 1 receptor inhibitor.

44 crophage function in ID8 mice using a colony-stimulating factor 1 receptor kinase inhibitor (GW2580).

45 of studies inhibiting the macrophage colony-stimulating factor 1 receptor,whereas the CD11b(+)/Ly6C(

46 omal dominant mutations in the CSF1R (colony-stimulating factor 1) gene.

47 interleukin 1 receptor antagonist and colony-stimulating factor 1, colony-stimulating factor 2 and in

48 ed such projections, concomitant with Colony stimulating factor 1-dependent changes in xanthophore di

49 is, illustrating the critical role of colony-stimulating factor 1-dependent monocyte/macrophage diffe

50 ligand 2 that stimulated migration of colony-stimulating factor 1-differentiated macrophages.

51 The cytokine colony stimulating factor-1 (CSF-1) acts as an important regula

52 Colony-stimulating factor-1 (CSF-1) is expressed by kidney tubu

53 crophage attractant and growth factor colony-stimulating factor-1 (CSF-1).

54 Patient data suggest that colony-stimulating factor-1 (CSF1) and its receptor (CSF1R) hav

55 s increased expression of xanthogenic Colony Stimulating Factor-1 (Csf1).

56 tion of TAM recruitment using an anti-colony-stimulating factor-1 antibody compromised the survival b

57 The colony-stimulating factor-1 receptor (CSF-1R) kinase regulates

58 and can be targeted via inhibition of colony-stimulating factor-1 receptor (CSF-1R) to regress high-g

59 is mediated by signaling through the colony-stimulating factor-1 receptor (CSF-1R) which is now know

60 e found that PLX3397, an inhibitor of colony stimulating factor-1 receptor (CSF-1R), blocks glioma pr

61 ound to be caused by mutations in the colony stimulating factor-1 receptor (CSF1R) gene.

62 Interestingly, colony stimulating factor-1 receptor (CSF1R) is significantly i

63 ered a dietary inhibitor (PLX5622) of colony stimulating factor-1 receptor (CSF1R) to deplete microgl

64 e E13.5 mouse fetal liver express the colony-stimulating factor-1 receptor (CSF1R), previously though

65 We then used the colony-stimulating factor-1 receptor inhibitor PLX5622 to deple

66 ture with the pro-macrophage cytokine colony stimulating factor-1 significantly enhanced soft callus

67 tatic site and granulocyte-macrophage colony-stimulating factor (125 mug/m(2) subcutaneously injected

68 nist and colony-stimulating factor 1, colony-stimulating factor 2 and interleukin 17F, without effect

69 The colony-stimulating factor 2 receptor beta subunit (Csf2rb), whi

70 trols for frameshift mutations in the colony-stimulating factor 2-receptor beta common subunit gene (

71 days 2-5 plus granulocyte macrophage colony-stimulating factor (250 mug/m(2) per dose) subcutaneousl

72 xpression of the neutrophil activator colony-stimulating factor 3 (CSF3) was suppressed in CD36(-/-)

73 prevalence (>80%) of mutations in the colony-stimulating factor 3 receptor (CSF3R).

74 nterleukin 10 receptor alpha subunit, colony stimulating factor 3 receptor and toll-like receptor 7 m

75 eukin-6, tumour necrosis factor-a and colony-stimulating factor 3), and antiinflammatory markers (inc

76 kin-3, interleukin-6, and granulocyte colony-stimulating factor (5 GFs) either alone or combined.

77 polymerase II, as well as levels of cleavage-stimulating factor 64 (Cstf64) and 73-kDa subunit of cle

78 (4.13 mg) and granulocyte macrophage colony-stimulating factor (75 mug), with one dose of cyclophosp

79 matory markers, including granulocyte colony-stimulating factor (adjusted OR 2.8 [95% CI 1.3-6.1]), I

80 ubcutaneous injections of granulocyte-colony-stimulating factor/AMD3100 to mobilize HSPCs from the bo

81 hages easily in vitro with macrophage colony-stimulating factor and human serum.

82 12 induction and improved granulocyte-colony stimulating factor and ischemia-induced mobilization, SC

83 d responses to granulocyte-macrophage colony-stimulating factor and markedly decreased activity of al

84 s in adulthood and raised granulocyte-colony stimulating factor and neutrophil counts/activity postsu

85 and CD1a with granulocyte-macrophage colony-stimulating factor and transforming growth factor beta a

86 rleukin-6, and granulocyte macrophage colony-stimulating factor) and hypothermia at 18 hours.

87 gonize GM-CSF (granulocyte macrophage colony-stimulating factor) and IL-2 (interleukin-2), two pleiot

88 sumably secreted), G-CSF (granulocyte-colony-stimulating factor) and MMP2 (matrix metalloproteinase 2

89 lating factor, granulocyte-macrophage colony-stimulating factor, and C-reactive protein at enrollment

90 e, IL-8, IL-1alpha, IL-6, granulocyte colony-stimulating factor, and GM-CSF levels.

91 id IL-1alpha, IL-6, IL-8, granulocyte colony-stimulating factor, and GM-CSF levels.

92 factor alpha, granulocyte-macrophage colony-stimulating factor, and granzyme B), and they were able

93 ated oncogene, granulocyte macrophage colony-stimulating factor, and IL-1beta.

94 pha and 1beta, granulocyte-macrophage colony-stimulating factor, and interferon-gamma were significan

95 ons of interleukin-1beta, granulocyte colony-stimulating factor, and matrix metalloproteinase 2 in ST

96 regulation, whereas CCL1, granulocyte colony-stimulating factor, and MIP1alpha were required for the

97 etic IL-7, and granulocyte macrophage colony-stimulating factor, and regulatory IL-10 were measured p

98 cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas.

99 erferon gamma, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor than MCAM(

100 eron-gamma and granulocyte-macrophage colony-stimulating factor are requisite factors in the tumor th

101 reports have identified hematopoietic colony-stimulating factors as important regulators of tumor- an

102 tic cells, and granulocyte-macrophage colony-stimulating factor at the same site.

103 depletion and granulocyte-macrophage colony-stimulating factor blockade.

104 Neutralizing granulocyte-colony stimulating factor blocked susceptibility to disease in

105 ma interferon, granulocyte-macrophage colony-stimulating factor) by CD4(+) and CD8(+) T cells, upregu

106 -kappaB) ligand (RANKL), a potent osteoclast-stimulating factor, by human periodontal ligament (hPDL)

107 with cyclophosphamide and granulocyte colony-stimulating factor, collected by peripheral blood leukap

108 imulation with granulocyte-macrophage colony-stimulating factor, compared with cells transfected with

109 enced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro.

110 Colony-stimulating factor (CSF)-1 and interleukin (IL)-34 are m

111 mmunity-related markers calprotectin, colony-stimulating factor (CSF)-1, macrophage migration inhibit

112 have previously shown that macrophage colony-stimulating factor (CSF-1; M-CSF) directly instructed my

113 rophages are controlled by macrophage colony-stimulating factor (CSF1).

114 d bacterial replication in macrophage colony-stimulating factor-differentiated macrophages more than

115 s more than in granulocyte-macrophage colony-stimulating factor-differentiated macrophages.

116 poietic stress, including granulocyte colony-stimulating factor, do not increase the mutation burden

117 ntation, a combination of granulocyte colony-stimulating factor, erythropoietin, aminocaproic acid, a

118 mg/m2 IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks).

119 , meropenem, and adjuvant granulocyte colony-stimulating factor for confirmed melioidosis sepsis in 1

120 proinflammatory cytokine granulocyte-colony-stimulating factor (G-CSF or Csf-3) as a key mediator of

121 hen forced into cycle via granulocyte colony-stimulating factor (G-CSF) administration.

122 f the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against storage at 4 degrees

123 migration by antagonizing granulocyte colony-stimulating factor (G-CSF) and chemokine receptor-mediat

124 om donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexamethasone.

125 he safety and efficacy of granulocyte colony-stimulating factor (G-CSF) and haemopoietic stem-cell in

126 verely reduced amounts of granulocyte colony-stimulating factor (G-CSF) and of nitric oxide (NO) upon

127 effects of the cytokines, granulocyte-colony stimulating factor (G-CSF) and stem cell factor (SCF) in

128 systemic up-regulation of granulocyte colony-stimulating factor (G-CSF) and the ELR(+) CXC chemokine

129 ial protective effects of granulocyte colony-stimulating factor (G-CSF) and underlying mechanisms in

130 ble for the production of granulocyte colony-stimulating factor (G-CSF) by hypoxic breast cancer cell

131 sm in which tumor-derived granulocyte-colony stimulating factor (G-CSF) directs expansion and differe

132 L, and median ANC without granulocyte colony-stimulating factor (G-CSF) during follow-up was 0.5 x 10

133 current administration of granulocyte colony-stimulating factor (G-CSF) enhanced RT-mediated antitumo

134 nt disadvantages of using granulocyte colony-stimulating factor (G-CSF) for hematopoietic stem cell (

135 Granulocyte colony-stimulating factor (G-CSF) has been shown to increase su

136 s, there is evidence that granulocyte-colony stimulating factor (G-CSF) in patients with glycogenosis

137 Granulocyte colony-stimulating factor (G-CSF) is a regulator of neutrophil

138 Human granulocyte colony-stimulating factor (G-CSF) is an endogenous glycoprotein

139 Granulocyte colony-stimulating factor (G-CSF) is used clinically to treat l

140 Granulocyte colony-stimulating factor (G-CSF) is widely used clinically to

141 ve protein 1 (MCP-1), and granulocyte colony-stimulating factor (G-CSF) levels in the amniotic fluid

142 Granulocyte colony stimulating factor (G-CSF) may enhance recovery from str

143 ulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF) preserves beta-cell function

144 btained by reducing human granulocyte-colony stimulating factor (G-CSF) prior to MS/MS and MS(3) anal

145 o describe outcomes after granulocyte colony-stimulating factor (G-CSF) prophylaxis in patients with

146 Using a granulocyte-colony stimulating factor (G-CSF) receptor knockout mouse model

147 rculation by the cytokine granulocyte colony-stimulating factor (G-CSF) through complex mechanisms.

148 (BMMC) and the ability of granulocyte colony-stimulating factor (G-CSF) to mobilize endogenous cells

149 on in neuronal cells, and granulocyte colony-stimulating factor (G-CSF) was chosen, due to its clinic

150 thymocyte globulin (ATG), granulocyte-colony stimulating factor (G-CSF), a dipeptidyl peptidase IV in

151 2-microglobulin (beta2m), granulocyte colony stimulating factor (G-CSF), and three monoclonal antibod

152 obilized with hydroxyurea+granulocyte colony-stimulating factor (G-CSF), G-CSF, Plerixafor, or Plerix

153 ting protein 78 (ENA-78), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colon

154 y factors including IL-8, granulocyte-colony stimulating factor (G-CSF), IL-33, IL-11, IL-1alpha, and

155 MIP-1beta, granulocyte colony-stimulating factor (G-CSF), interleukin-12/23 (IL-12/23)

156 a interferon (IFN-gamma), granulocyte colony-stimulating factor (G-CSF), monocyte chemoattractant pro

157 1 synergistically induced granulocyte colony-stimulating factor (G-CSF), which was required for extra

158 s, and downregulated upon granulocyte-colony stimulating factor (G-CSF)- mediated granulocytic differ

159 after transplantation of granulocyte colony-stimulating factor (G-CSF)-mobilized blood cells from HL

160 s, promoting an excessive granulocyte colony-stimulating factor (G-CSF)-regulated neutrophilic respon

161 ars in the circulation of granulocyte colony-stimulating factor (G-CSF)-treated donors (GDs) consists

162 dard multi-day regimen of granulocyte colony-stimulating factor (G-CSF).

163 bilization in response to granulocyte colony-stimulating factor (G-CSF).

164 e to the up-regulation of granulocyte-colony stimulating factor (G-CSF); these effects are reversed f

165 Human granulocyte colony-stimulating factor (GCSF) is a well-known cytokine for n

166 Granulocyte-macrophage colony-stimulating factor (GM-CSF or Csf-2) is a pro-inflammato

167 in (IL)-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (oAd) and DCs for sustained

168 )-3, IL-5, and granulocyte macrophage-colony-stimulating factor (GM-CSF) and can result from enhanced

169 gel containing granulocyte macrophage colony-stimulating factor (GM-CSF) and CpG ODN1826 (CpG), which

170 breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF) and matrix metallopeptidase

171 the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) and peptide vaccination (PV)

172 including anti-granulocyte macrophage colony-stimulating factor (GM-CSF) autoantibodies with cryptoco

173 kin-23 (IL-23)-granulocyte macrophage colony-stimulating factor (GM-CSF) axis in colitis.

174 uctions of the granulocyte-macrophage colony-stimulating factor (GM-CSF) by central nervous system (C

175 IP-1alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) can enhance the immunogenici

176 onstrated that granulocyte macrophage colony-stimulating factor (GM-CSF) can function as a key proinf

177 ort that human granulocyte macrophage-colony stimulating factor (GM-CSF) can sensitize the persister

178 n 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF) drive dendritic cell differe

179 okines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances eosinophil migratio

180 Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF) for improving walking abilit

181 nce shows that granulocyte macrophage colony-stimulating factor (GM-CSF) has progression-promoting po

182 t Shp2 induces granulocyte macrophage-colony-stimulating factor (GM-CSF) hypersensitivity and that th

183 ntial role for granulocyte/macrophage colony-stimulating factor (GM-CSF) in orchestrating these event

184 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a medicinally important g

185 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic cytokine th

186 e we show that granulocyte macrophage colony-stimulating factor (GM-CSF) is a triggering molecule for

187 atory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) is EGFR dependent in keratin

188 the increased granulocyte-macrophage colony-stimulating factor (GM-CSF) level in the EDM-TTF-1(+) co

189 bodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumor necrosis factor (TN

190 ro-M1 cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) plus blockade of the M2 cyto

191 Granulocyte-macrophage colony-stimulating factor (GM-CSF) produced by T helper 17 (Th1

192 tor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) resembled in vivo inflammato

193 or blockade of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in SFB-colonized m

194 nisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally maintains

195 y defenses via granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, which stimulates

196 blasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF) that acts locally and distal

197 nin (KLH) plus granulocyte macrophage colony-stimulating factor (GM-CSF) to a control immunotherapy w

198 rs and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumo

199 BM) cells with granulocyte-macrophage colony-stimulating factor (GM-CSF) to generate BM-derived DCs (

200 Ipilimumab and granulocyte macrophage colony stimulating factor (GM-CSF) was presented in the supplem

201 ses that human granulocyte-macrophage colony-stimulating factor (GM-CSF), a clinically used cytokine,

202 JMML cells to granulocyte macrophage-colony-stimulating factor (GM-CSF), a unifying characteristic i

203 actor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), IL-8, IL-18, monocyte chemo

204 a (TNF-alpha), granulocyte macrophage colony stimulating factor (GM-CSF), interleukin 6 (IL-6) among

205 Granulocyte-macrophage colony-stimulating factor (GM-CSF), mainly produced by MDSCs, w

206 oluble ligands granulocyte macrophage colony-stimulating factor (GM-CSF), transforming growth factor

207 he presence of granulocyte/macrophage colony-stimulating factor (GM-CSF), we used GM-CSF-deficient (C

208 production of granulocyte macrophage-colony stimulating factor (GM-CSF), which recruits and maintain

209 ngly augmented granulocyte-macrophage-colony-stimulating factor (GM-CSF)-induced differentiation of p

210 Ms), including granulocyte macrophage colony-stimulating factor (GM-CSF)-polarized M1 and macrophage

211 4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine comb

212 by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF).

213 (IFN-gamma) and granulocyte monocyte colony stimulating factor (GM-CSF).

214 -2, IL-15, and granulocyte-macrophage colony-stimulating factor (GM-CSF).

215 sensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).

216 arrow cells by granulocyte-macrophage colony-stimulating factor (GM-CSF)/G-CSF in vitro, inhibited GV

217 Granulocyte macrophage colony-stimulating factor (GM-CSF, Csf2) is a growth factor for

218 that targeting granulocyte-macrophage colony-stimulating factor (GM-CSF; an agonist cytokine linked w

219 , IL-13, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF], IL-4, and MIP-1alpha) respo

220 oinflammatory (granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophage colony-stimulati

221 L-1beta, IL-1alpha, IL-6, granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimul

222 erythropoietin (hEPO) or granulocyte colony-stimulating factor (hGCSF) was independently fused into

223 e secretion of granulocyte macrophage-colony stimulating factor, IL-12, -13, and -15, which was preve

224 erferon-gamma, granulocyte macrophage colony-stimulating factor, IL-13).

225 ificantly lower levels of granulocyte colony stimulating factor, IL-8, macrophage inflammatory protei

226 adjunctive treatment with granulocyte colony-stimulating factor in 1998.

227 pathophysiologic role of granulocyte colony-stimulating factor in exacerbation of preexisting GN.

228 precursors were induced by macrophage colony-stimulating factor in the presence of OEBFs, the generat

229 clear factor kappaB ligand/macrophage colony-stimulating factor induction of nuclear factor of activa

230 kines, such as granulocyte macrophage colony-stimulating factor, interferon-gamma, interleukin-1alpha

231 nterleukin-17, granulocyte-macrophage colony-stimulating factor, interleukin-1beta, and interleukin-7

232 subunit of the granulocyte-macrophage colony-stimulating factor/interleukin-3 receptor driving glycol

233 Granulocyte-macrophage colony-stimulating factor is a potent stimulator of dendritic c

234 Granulocyte-macrophage colony-stimulating factor is a potential therapeutic target to

235 aphy of recombinant human granulocyte colony stimulating factor is demonstrated.

236 e inflammatory protein-2, granulocyte colony-stimulating factor, keratinocyte chemoattractant) in res

237 10-14; two cycles), with granulocyte-colony stimulating factor (lenograstim) support.

238 phages differentiated with macrophage colony-stimulating factor (M-CSF) alone (termed M0) did.

239 is medium with 20 ng/mL of macrophage colony-stimulating factor (M-CSF) and 50 ng/mL of receptor acti

240 acrophages stimulated with macrophage colony-stimulating factor (M-CSF) and granulocyte-M-CSF (GM-CSF

241 cular interactions between macrophage colony-stimulating factor (M-CSF) and the tyrosine kinase recep

242 -kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) as well as BMSC CM from each

243 e investigated the role of macrophage colony-stimulating factor (M-CSF) in TAM differentiation and po

244 onocytes differentiated by macrophage colony-stimulating factor (M-CSF) or granulocyte macrophage col

245 (HDLS), which is caused by macrophage colony-stimulating factor (M-CSF) receptor mutations.

246 topoietic progenitors with macrophage colony-stimulating factor (M-CSF) resulted in mTORC1-dependent

247 Macrophage colony stimulating factor (M-CSF) was implicated as a contribut

248 (GM-CSF)-polarized M1 and macrophage colony-stimulating factor (M-CSF)-polarized M2, but not human A

249 hage glucose metabolism by macrophage colony-stimulating factor (M-CSF; inflammation resolving) and g

250 m cytokines and identified macrophage colony-stimulating factor (MCSF) as one of the elevated cytokin

251 ow that strategies targeting monocyte colony-stimulating factor (MCSF) signaling could be used to pro

252 n B and another activator, macrophage colony-stimulating factor (MCSF), further elevated the represen

253 imulating factor [GM-CSF], macrophage colony-stimulating factor [MCSF], interleukin-6 [IL-6], IL-8, I

254 iotherapy with granulocyte-macrophage colony-stimulating factor might result in abscopal responses am

255 bine plus cytarabine plus granulocyte colony-stimulating factor, mitoxantrone plus cytarabine, or hig

256 either marrow (n = 4) or granulocyte-colony stimulating factor mobilized peripheral blood stem cells

257 unctional human MEPs from granulocyte colony-stimulating factor-mobilized peripheral blood and bone m

258 ismatched, unrelated, and granulocyte colony-stimulating factor-mobilized peripheral blood stem cell

259 ne cells contained within granulocyte colony-stimulating factor-mobilized peripheral blood stem cell

260 interleukin (IL)-6, IL-8, granulocyte colony-stimulating factor, monocyte chemoattractant protein-1,

261 l depletion or granulocyte-macrophage colony-stimulating factor neutralization inhibited DC and T-cel

262 neutrophil functions via granulocyte colony-stimulating factor neutralization significantly diminish

263 ctivity, whereas coronavirus nsp16 needs the stimulating factor nsp10 for its full activity.

264 ockade of the M2 cytokines macrophage colony-stimulating factor or MIF.

265 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.001), thus contributing to mig

266 d with elevated levels of granulocyte colony-stimulating factor (P = .02).

267 farabine, cytarabine, and granulocyte-colony stimulating factor priming.

268 Filgrastim, an analog for granulocyte colony-stimulating factor produced by recombinant DNA technolog

269 iotherapy with granulocyte-macrophage colony-stimulating factor produced objective abscopal responses

270 ted numbers of granulocyte-macrophage colony-stimulating factor-producing B cells within pericardial

271 Granulocyte macrophage colony-stimulating factor-producing IRA B cells alter adaptive

272 ma, IL-15, and granulocyte-macrophage colony-stimulating factor protected from subsequent malaria, in

273 d responses to granulocyte-macrophage colony-stimulating factor, providing an additional mechanism fo

274 ons in CSF3R encoding the granulocyte colony-stimulating factor receptor (G-CSFR) in approximately 80

275 ecurrent mutations in the granulocyte colony-stimulating factor receptor gene CSF3R, which signals th

276 mice (mice expressing the macrophage colony-stimulating factor receptor GFP transgene throughout the

277 locus vs GM-CSF-alpha and macrophage-colony-stimulating factor receptor loci.

278 interleukin 3/granulocyte-macrophage colony-stimulating factor receptor signaling in bone marrow mye

279 (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL) whereas CALR or MP

280 ytokine receptors, except granulocyte colony-stimulating factor receptor, which supported only transi

281 Granulocyte-macrophage colony-stimulating factor-receptor-alpha expression patterns we

282 Granulocyte-macrophage colony-stimulating factor-receptor-alpha was predominantly expr

283 surface IL-3 and granulocyte-monocyte colony-stimulating factor receptors, CD69, CD44, and CD23 and d

284 of CSF2RB and granulocyte-macrophage colony-stimulating factor-responsive cells were defined by aden

285 eukocytes with granulocyte-macrophage colony-stimulating factor resulted in high levels of phosphoryl

286 oring Cebpa expression by granulocyte colony-stimulating factor reverses the db phenotype and rescues

287 ombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) (1 ng/mL for 6 h).

288 ombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) as a model drug, the prese

289 GVAX pancreas, granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor

290 e morphogenetic protein 7, macrophage colony-stimulating factor, stromal cell-derived factor-1, tissu

291 tory adjuvants granulocyte-macrophage colony-stimulating factor, Toll-like receptor (TLR) ligands, an

292 by GM-CSF, did not affect macrophage-colony-stimulating factor-triggered differentiation to macropha

293 okine response comprising granulocyte colony-stimulating factor, tumor necrosis factor alpha, and sev

294 The protein therapeutic granulocyte-colony stimulating factor was analyzed using a Thermo Fusion Tr

295 Granulocyte colony-stimulating factor was prohibited.

296 N-gamma, IL-12, IL-6, and granulocyte colony-stimulating factor were significantly reduced, while mon

297 Therapeutic colony-stimulating factors were associated with a 1.42-day redu

298 s encodes the receptor for macrophage colony-stimulating factor, which controls the proliferation, di

299 given inhaled granulocyte-macrophage colony-stimulating factor with first pulmonary recurrence who h

300 sensitivity to granulocyte-macrophage colony-stimulating factor with myeloid cell dysplasia and ineff